

**Michael O. Favorov, M.D., Ph.D., D.S.**

---

---

Phone: +1 772 905 2661

Email: [favorov@diaprepsystem.com](mailto:favorov@diaprepsystem.com)

**Overview**

Accomplished public health (PH) expert with extensive high-level experience working for the CDC (more than 20 years) and other International Organizations. Proven track record of developing public health programs in the area of infection diseases including SARS-1, COVID-19, Viral Hepatitis (VH) A, B, C, D, and E, HIV, TB, surveillance, diagnostics, improvement of laboratory management systems, outbreak investigations, vaccine trials, designing and implementing international policy for PH program strengthening.

**Work**

**Experience:**

**President, DiaPrep System Inc.,**  
Atlanta, GA, United States

**05/2018 - present time**

**DiaPrep System Inc.** (<https://en.diaprepsystem.com/about-us>)

- Provides a wide range of advisory services for strategic planning, development, and improvement of national health policy and programming models, based on evidence-based approaches that contribute to the modernization, rationalization, and effectiveness of interventions to improve public health.
- Supports the public health care efforts of government, private, and non-profit institutions in pursuing the goals of well-being and of protecting public health. Assists with improving the education levels of medical service providers.
- Promotes the use of modern, reliable, and affordable diagnostic tools for the control and prevention of socially significant infectious diseases and helps strengthen laboratory systems to ensure high-quality standards of testing.

**Chief Scientific Officer, Turklab** (<https://www.turklab.com.tr/>)  
Turkey

**06/2019 - present time**

- Assists with establishing scientific direction and strategies; makes recommendations on new research opportunities and technologies. Including COVID-19 diagnostic capability development and implementation for PH settings.
- Provides technical support on research and development of new products; serves as principal investigator for research projects.
- Guides scientific publications, writing grant proposals and ensuring that projects are designed to meet public health needs.

**Associate Chief for Central & Eastern Europe, International Laboratory Branch, 06/2014 – 05/2018**  
**Division of Global Health HIV/AIDS, Centres for Disease Control and Prevention**

- Helped modify national health policies in Kazakhstan, Kyrgyzstan, Tajikistan, and Uzbekistan to expand HIV testing capacities and improve HIV treatment and care programs in the region.
- Coordinated regional HIV laboratory capacity building activities, including those on HIV molecular testing. Ensured strategic and field support for comprehensive laboratory quality management system (QMS) implementation in Central Asia.
- Worked in close collaboration with the Global Fund (GF) and regional WHO programs on:
  - HIV laboratory capacity building strategies.
  - Consolidation of regional action plans and implementation procedures
  - Evaluation of HIV program practices and development of approaches for providing measurable results in compliance with PEPFAR, GF, and WHO requirements.

**Deputy Director-General, International Vaccine Institute**

**03/2008-06/2011**

Seoul, South Korea

- Provided scientific leadership, support and oversight to the Translational Research Division in the Institute while leading several global public health programs designed to increase the evidence-based practice for public health among various countries in Asia and Africa.
- Designed and implemented several independently funded studies focusing on epidemiology of vaccine preventable diseases, laboratory diagnostic, vaccines, and vaccination programs in several countries, including Pakistan, Uzbekistan, India, Vietnam, Philippines, Madagascar, South Africa and Kenya and others. Managed an annual budget of more than 30 million USD
- Conceptualized, designed, and assembled a research team to conduct a comprehensive multi-country TB program evaluation to identify deaths averted by DOTS implementation; the research team also evaluated TB diagnostic, prevention, effectiveness of BCG vaccines through controlled multiple cohort studies in Kazakhstan.
- Introduced nationwide evidence-based vaccination policy, including BCG vaccination.
- In multiple countries, led multiple field studies to characterize disease burden, conduct pre-licensure clinical evaluations, and implement several demonstration projects designed to assess feasibility and impact of new vaccines.
- Assess status of laboratory practices (facilities, personnel, equipment, and testing methods), and the quality of the results is assured (e.g. proficiency testing, internal and external audits, personnel competency evaluation, etc.) as part of vaccine related studies in developing countries.
- In multiple countries, conducted several policy analyses to evaluate prospective vaccine channels for introducing new vaccines and created an equitable model for indigenous and sustainable financing.

- Designed multiple training programs for epidemiologists, public health managers, and lab specialists, to increase the practice of public health by using a “case study approach” for the control of highly prevalent threats to the health of the public, including typhoid, tuberculosis, and cholera.

**CDC Central Asia Regional Director**

**11/2000 - 03/2008**

**Centers for Disease Control and Prevention  
Central Asia Regional Office**

- Provided supervision and scientific leadership to the USAG-supported five country program of the U.S. Centers for Disease Control (CDC) in Central Asia, with offices in Kazakhstan, Kyrgyzstan, Uzbekistan, Turkmenistan, and Tajikistan. Supervised and led a team of 46 scientists and program staff in five countries and managed an annual budget of more than 8 million USD.
- Oversaw development and evaluation activities involving collaboration with counterparts related to establishing epidemiology-laboratory related training programs Central Asia.
- Managed and coordinated funding from U.S. Agency for International Development (USAID) and Soros Foundation for epidemiology-laboratory training courses from Russian at CDC Atlanta for 54 physicians from the former Soviet Union.
- Assisted in directing and coordinating CDC’s activities in Central Asia to develop and implement appropriate policies for infectious disease control. This included guiding the CDC Regional Office (a public health advisor and four locally-hired staff) in Almaty, Kazakhstan, with support from USAID.
- Coordinated establishing a regional HIV, hepatitis reference laboratories in the region, national tuberculosis laboratories in Kazakhstan and Uzbekistan. Provided the technical assistance the region to initiate immunization of birth cohorts with hepatitis B vaccine.
- Coordinated an epidemiologic and laboratory investigation into characterization of cases of anthrax infection observed over 20 years in Kazakhstan.
- Assisted in creation and support of the worldwide organization of Training Programs in Epidemiology for Public Health Interventions Network (TEPHINET) (cf. Am J Public Health 2002;92:196-7). Designed, implemented, and evaluated multiple pioneering epidemiology and laboratory studies in the region, mobilized a coordinated multiple country strategy to build indigenous capacity to respond to these threats. Control strategies concerned TB, HIV, polio, malaria, and other infectious diseases in countries of Central Asia and several neighboring countries, including the Russian Federation, Azerbaijan, Belarus, Georgia, Moldova, and Ukraine
- Mobilized multiple, multi-country outbreak investigations of TB (including multidrug-resistant -TB (MDR-TB), HIV/AIDS, viral hepatitis, and several special pathogens including anthrax, botulism, plague, hemorrhagic fevers, and other infectious diseases in five countries of the Central Asia Region, and helped build national disease specific surveillance and response capacity.

- Designed, evaluated, and supported the adoption of integrated routine surveillance for HIV/hepatitis C (HCV)/syphilis surveillance programs among high-risk groups, design and improve laboratory system capacity, building and strengthening laboratory related activities in Kazakhstan, Kyrgyzstan, Tajikistan, and Uzbekistan.
- Led a multi-country process to establish the first national public health reference laboratories for hepatitis in Kazakhstan, Kyrgyzstan, Uzbekistan, Turkmenistan, and Tajikistan, and instituted the regions first laboratory quality control program.
- Founded the first Central Asia Regional Infectious Disease Working Group, a multi-country knowledge base, which tackled issues of public health policy, educational programs, regulatory actions, and supported evidence-based decision making with a special focus on infectious diseases including anthrax, plague, and hemorrhagic fever throughout the region.
- Established a network of scientists, government officials, and public health professionals in Kazakhstan, Kyrgyzstan, Uzbekistan, Turkmenistan, and Tajikistan to prevent and control TB, HIV, malaria, and emerging infections.
- Initiated a malaria eradication campaign in Kazakhstan, Kyrgyzstan, Uzbekistan, Turkmenistan, and Tajikistan, with Tajikistan being the first country to eradicate malaria.
- Designed and led a process that established the first Field Epidemiology/Laboratory Training Programs (FELTP) in Kazakhstan, Kyrgyzstan, Uzbekistan, Turkmenistan, and Tajikistan. These FELTPs investigated more than 80 disease outbreaks, and more than 20 studies were conducted by FELTP officers, including a vaccine study which resulted in the adoption of a more effective Hepatitis A prevention strategy in the region and approx. 3,000 lives saved annually in Central Asia as a result of initiating and establishing policy for hepatitis B (HBV) universal immunization across the five countries.
- Provided frequent written reports and recommendations to the U.S. Ambassadors and CDC leadership and to the Ministries of Health and delivered frequent high level presentations on HIV/AIDS epidemiology in Central Asia to key stakeholders, including Ministries of Health, CDC program staff, US Embassies, and international organizations.

**Senior Service Fellow**

**07/1998 - 11/2000**

**Centers for Disease Control and Prevention**

**Division of International Health, CDC**

Atlanta, GA, United States

- Planned, designed, implemented and evaluated multiple epidemiologic studies, surveys and investigations of viral hepatitis.
- Pioneered the regions first integrated disease-specific infectious disease surveillance systems in highly endemic areas of Asia and Central Asia.

- Managed and coordinated funding from U.S. Agency for International Development (USAID) and Soros Foundation for epidemiology courses in Russian at CDC for 54 physicians from the former Soviet Union. Assisted in directing and coordinating CDC's activities in Central Asia to develop and implement appropriate policies for infectious disease control. This included guiding the CDC Regional Office (a public health advisor and four locally-hired staff) in Almaty, Kazakhstan, with support from USAID.
- Established and strengthened multiple national public health reference laboratories and improved quality control programs in developing and transitional economic countries, in Eastern Europe and other countries of the former Soviet Union.
- Coordinated an epidemiologic and laboratory investigation into characterization of cases of anthrax infection observed over 20 years in Kazakhstan.
- Design, coordinated and provide methodological support of population-based study on Hepatitis C prevalence among risk groups in Russia
- Assisted in coordinating an evaluation of a WHO-funded trial of Directly-Observed Short-Course Therapy (DOTS) for tuberculosis in Kyrgyzstan. Based on results of this evaluation and subsequent training efforts, neighboring Kazakhstan changed its national policy in 1998 for surveillance, diagnosis, treatment, and control of tuberculosis, reflecting WHO recommendations. Provided the technical assistance for Kazakhstan to develop a national DOTS program for tuberculosis. As of July 2005, it was estimated that this change of policy had resulted in 18,000 lives saved in a 7-year period.

**Science Fellow**

**06/1991 - 07/1998**

**Centers for Disease Control and Prevention**

**Division of Hepatitis Control**

Atlanta, GA, United States

- Designed laboratory diagnostic tests for hepatitis E virus (HEV) and completed seroprevalence studies of infection in the United States, Israel, Ukraine, Turkmenistan, Venezuela, South Africa, Moldova, Russia, India, Kenya, and Italy. This test is the gold standard for detecting HEV in blood.
- Introduced pioneer confirmatory test for HEV by using western blot principles for anti-HEV confirmation with antigen differ then immune-assay based HEV recombinant antigen
- Researched hepatitis D (HDV) virus in its naturally occurring environment, HDV recombinant antigens, and diagnostic capacity for HDV.

**Director Clinical & Diagnostic Department of Viral Hepatitis**

**06/1989 - 06/1991**

**D.I. Ivanovsky Institute of Virology**

Moscow, USSR

**Center Director,  
Soviet Union National Center for Viral Hepatitis  
WHO Collaborating Center of Excellence**  
Moscow, USSR

- Developed a novel diagnostic test for hepatitis C virus (HCV) anti-IgM.
- Evaluated disease-specific surveillance systems, studies of epidemiological trends, and sero-surveys in various parts of Eastern Europe and the former Soviet Union.
- Oversaw hepatitis A and B vaccine trials and vaccine evaluation programs in endemic areas.

**Senior Researcher**  
**D.I. Ivanovsky Institute of Virology**  
Moscow, USSR

**06/1985 - 06/1989**

- Planned, prioritized, and managed research on various aspects of viral hepatitis infections.
- Determined etiology of fulminant and chronic forms of hepatitis and developed a diagnostic test for hepatitis infections.
- Conceptualized and developed principles for diagnostic and case management of viral hepatitis including fulminant HEV infection among pregnant women.
- Established principles for using interferon in the treatment of acute and chronic forms of HCV and HDV infections.
- Oversaw the launch of a national viral hepatitis reference laboratory in countries of former Soviet Union.
- Spearheaded comparative epidemiological analyses of viral hepatitis outbreaks in China and Central Asian Republics in tandem with the National Institute of Virology in Beijing.
- Supervised clinical trials of interferon and antiviral.

**Associate Researcher**  
**D.I. Ivanovsky Institute of Virology**  
Moscow, USSR

**06/1980 - 06/1985**

- Directed epidemiologic investigations of fecal-orally transmitted viral hepatitis non-A and non-B.
- Designed and developed immune-diagnostic tests for hepatitis viruses using enzyme immune assay and Western Blot analysis.
- Orchestrated prevention measures in various highly endemic regions.

**Research Assistant**

**06/1977 - 06/1980**

**D.I. Ivanovsky Institute of Virology**

Moscow, USSR

- Epidemiologic investigations of fecal-orally transmitted viral hepatitis non-A and non-B.
- Implementation of prevention measures in various regions of high endemicity.
- Designed and developed immune-diagnostic tests for hepatitis viruses using enzyme immune assay and Western Blot analysis.

**Physician**

**06/1976 - 06/1977**

**First Moscow Infectious Diseases Hospital**

Moscow, USSR

- Provided patient care in the infective diseases intensive care department

**Education: American Association of Collegiate Registrars and Admission Offices**

Washington, DC United States

Medical Doctorate 06/1988

**Major:** Ph.D. Infectious Disease

**Relevant Coursework, Licenses and Certifications:**

American Association of Collegiate Registrars and Admission Offices

Evaluation of International Educational Credentials

Transcript of Academic records - Ph.D.

**Moscow Medical School** Moscow, Russia

Master's Degree 06/1975

**Major:** General Medicine **Minor:** Infectious Diseases

**Residency (Infectious Disease)** Moscow, USSR, 1976-1977 , Master's Degree

**Doctor of Medical Science (Epidemiology and Infectious Diseases)** Moscow, USSR, 1988 USSR, Doctorate

**Awards:**

- The United States Ambassador's **Distinguished Service Award** for positive impact on the growth and development of public health in the Central Asian Region in Public Health, 2006, 2008
- The United States Agency for International Development **Meritorious Honor Award** for outstanding performance in the prevention and response to infectious diseases in the countries of Central Asia, 2006.
- The United States Center for Disease Control and Prevention **Honor Award for Global Health Achievement**, 2006
- Kazakhstan, Uzbekistan, and Kyrgyzstan Republics - **Medals of Honor for Excellence in Public Health**, 2008
- M.S. Balayan's **Medal for the Contribution to the Study of Hepatitis E.**, 2015

- Affiliations**
- TEPHINET - Board Member 1998-2013
  - WHO experts group, TB control and prevention, monitoring and evaluation - Working Group Member
  - American Society of Microbiology – Member
  - WHO experts, Typhoid Fever diagnostic, control and prevention – Member 2008-2012
- Patents:**
- U.S. Patent # 5,445,932, issued August 29, 1995. Method for Detection of a New Marker Associated with Hepatitis Delta Virus Infection.
  - U.S. Patent # 5,563,032, issued October 8, 1996. Mosaic Polypeptide and Methods for Detecting the Hepatitis E Virus.
  - U.S. Patent # 6,022,685, issued February 8, 2000. Methods and Composition for Detecting Anti-Hepatitis Virus Activity.

**Co-authored more than 100 publications. Citation 3287; h-index 33**

**List (1) of selected publications on PH program and epidemiology:**

1. **М.О. Фаворов**, Е.М. Белиловский, С.А. Турсунбаева, Ш.Ш. Исмаилов; Эффективность трех коммерчески доступных вакцин Бацилла Кальметта-Герена для профилактики туберкулёза у детей; результаты когортного, контролируемого, ретроспективного анализа. 2019, Журнал: Инфекционные болезни: Новости, мнения, обучение. [http://infect-disease-journal.ru/patrn/pdf/infectii\\_1\\_2020.pdf?fbclid=IwAR2XuebC4GeB5stksxDTyphiKf99BisYGc2Bo4brOfR2JAuVowpnpj2EGZO](http://infect-disease-journal.ru/patrn/pdf/infectii_1_2020.pdf?fbclid=IwAR2XuebC4GeB5stksxDTyphiKf99BisYGc2Bo4brOfR2JAuVowpnpj2EGZO) P 8-18
2. **Favorov M.O.**, Mikhailov M.I., Musabaev E.I.; Neglected HBV/HDV epidemic in Eastern Europe and Central Asia: Policy modification requirements for effective treatment and elimination. International Liver Foundation's Newsletter, June, 2019 - <https://easl-ilf.org/wp-content/uploads/2019/06/5.NEGLECTED-HBV-HDV-Favorov.pdf>
3. Pach A, Tabbusam G, Khan MI, Suhag Z, Hussain I, Hussain E, Mumtaz U, Haq IU, Tahir R, Mirani A, Yousafzai A, Sahastrabuddhe S, Ochiai RL, Soofi S, Clemens JD, **Favorov MO**, Bhutta ZA; Formative research and development of an evidence-based communication strategy: the introduction of vi typhoid Fever vaccine among school-aged children in Pakistan. J Health Commun. 2013 Mar;18(3):306-24. doi:10.1080/10810730.2012.727958. Epub 2013 Jan 18.
4. **M. Favorov**, M. Ali, A. Tursunbayeva, I. Aitmagambetova, P. Kilgore, S. Ismailov, T. Chorba; Comparative tuberculosis (TB) prevention effectiveness of Bacillus Calmette-Guérin (BCG) vaccines from different producers among children; PLOS ONE; 2012; <http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0032567>
5. S.B.Soofo, I. Hag, I.Khan, M.B.Siddiqui, M.Mirani, R.Tahir, I.Hussain, M. Puri, Z.H.Suhag, A.R. Khuwaja, A. R. Lasi, J.D. Clemens, **M. Favorov**, R. L.Ochiai, Z.A. Bhutta; Schools as potential vaccination venue for vaccines outside regular EPI schedule: results from a school survey in Pakistan. BMC Res Notes. 2012; 5:6. [http://www.biomedcentral.com/imedia/3328960355342213\\_article.pdf](http://www.biomedcentral.com/imedia/3328960355342213_article.pdf)



6. Dang Duc Anh, Anna Lena Lopez, Vu Dinh Thiem, Shannon L. Grahek, Tran Nhu Duong, Jin Kyung Park, Hye Jung Kwon, **Michael Favorov**, Nguyen Tran Hien, John D. Clemens; Use of oral cholera vaccines in an outbreak in Vietnam: A case control study; PLoS Negl Trop Dis 5(1)
  - a. <http://www.plosntds.org/article/info%3Adoi%2F10.1371%2Fjournal.pntd.0001006>
7. **Kim Soon Ae**, Michael O. Favorov. 2010. A survey on pneumococcal and influenza vaccination among the elderly, Incheon, Korea. **BOOK CHAPTER** Community Chest of Korea and International Vaccine Institute.
8. F. Marks, Ya. Adu-Sarkodie, F. Hüniger, N. Sarpong, S. Ekuban, A. Agyekum, B. Nkrumah, N. Schwarz, **M. Favorov**, Ch. Meyer, J. May; Typhoid fever among children, Ghana, Emerging Infectious Diseases, Vol. 16, No. 11, 1796-1797
9. Senouci K, Blau J, Nyambat B, Coumba Faye P, Gautier L, Da Silva A, **Favorov MO**, Clemens JD, Stoeckel P, Gessner BD; The Supporting Independent Immunization and Vaccine Advisory Committees (SIVAC) initiative: a country-driven, multi-partner program to support evidence-based decision making. Vaccine. 2010 Apr 19;28 Suppl 1:A26-30. doi: 10.1016/j.vaccine.2010.02.028.
10. **M. Favorov**, E. Belilovsky, I. Aitmagambetova, S. Ismailov, M. White, T. Chorba; Tuberculosis deaths averted by implementation of the DOTS strategy; Int J Tuberc Lung Dis 14(12):1582–1588
11. Khan MI, Ochiai RL, von Seidlein L, Dong B, Bhattacharya SK, Agtini MD, Bhutta ZA, Do GC, Ali M, Kim DR, **Favorov M**, Clemens JD. Non-typhoidal Salmonella rates in febrile children at sites in five Asian countries. Trop Med Int Health. 2010 Jun 9.
12. Sharapov M.B., **Favorov M.O**, Yashina T.L, Brawn M.S., Onischenko G.G, Margolis H.S., Chorba T.L. Acute viral hepatitis morbidity and mortality associated with hepatitis E virus infection: Uzbekistan surveillance data. BioMedCentral Infectious Diseases, 2009. <http://www.biomedcentral.com/1471-2334/9/35> (Nominated For demonstrating excellence in science for the Charles C. Shepard Science Award, Prevention and Control, CDC, 2009)
13. Victor J.C., Monto A.S., Surdina T.Y., Suleimenova S.Z., Vuughan G., Nayan O.V., **Favorov M.O.**, Margolis H.S., Bell B.P., Hepatitis A vaccine versus immune globulin for postexposure prophylaxis. New England Journal Of Medicine, 357:17; 1685-1693
14. Ye.M. Belilovsky, **M.O. Favorov**, I. Aitmagambetova, A.M. Ubaidulaev, G.T. Uzakova, A.A. Yuldashev, Sh.Sh. Ismailov, A. Sh. Alisherov. Surveillance of tuberculosis in countries of Central Asia by the electronic monitoring data system. Tuberculosis and Lung Diseases, September, 2008
15. B. Zhusupov, A. Shakarishvili, G. Muratbayeva, R. Bronzan, C. Ryan, **MO Favorov**. Study of safe and risky behavior in relation to HIV Infection, STI and viral hepatitis among injecting drug users In Temirtau and Karaganda – 1. Republic Of Kazakhstan, 2007, Book, 162 Pages, ISBN 9965-32-382-8
16. E. Bumburidi, S. Ajeilat, A. Dadu, I. Aitmagambetova, J. Ershova, R. Fagan, **MO Favorov**. Progress toward tuberculosis control and determinants of treatment outcomes - Kazakhstan, 2000-2002 –MMWR, April 28, 2006 / 55 (SUP01); 11-15.

17. AS Yassin, **M.O. Favorov**, ES Maes, R Sadek, A Jumagulova, V Merker, T Surdina, T Chorba. Cost-Analysis of different management policies for patients with mild hepatitis A In Kazakhstan. Cost Effectiveness And Resource Allocation, Volume 3, 12 May 2005. Available At <http://www.Resource-Allocation.Com/Content/3/1/4> (*Nominated for demonstrating excellence in science for the Charles C. Shepard Science Award, Prevention and Control, CDC, June 14, 2006*)
18. J.C. Victor, T.Y. Surdina, S.Z. Suleimenova, **M.O. Favorov**, B.P. Bell, and A.S. Monto. Person-To-Person Transmission Of Hepatitis A virus in an urban area of intermediate endemicity: Implications for vaccination strategies. *Am J Epidemiol.* 2006 Feb 1;163(3):204-10. Epub 2005 Dec 7.
19. I. Usmanov, **M. O. Favorov**, T. L. Chorba. Universal Immunization: The Diphtheria Control Strategy of Choice in the Republic of Tajikistan, 1993–1997; *The Journal of Infectious Diseases*, Volume 181, Issue Supplement\_1, 1 February 2000, Pages S86–S93, <https://doi.org/10.1086/315545>

**List (2) - selected publications on diagnostics and laboratory science:**

1. X-Y. Wang, P. Kilgore, K Lim, S-M. Wang, J. Lee, W. Deng, M-Q. Mo, B. Nyambat, J-Ch. Ma, **M. Favorov**, J. Clemens; Influenza and Bacterial Pathogen Co-infections in the 20th Century, *Interdisciplinary Perspectives on Infectious Diseases*, vol. 2011, doi:10.1155/2011/146376; <http://www.hindawi.com/journals/ipid/2011/146376/>
2. Baker s, **Favorov M**; Dougan G; *BMC Infectious Diseases*; Searching for the elusive typhoid diagnostic, 2010 [www.biomedcentral.com/1471-2334/10/45](http://www.biomedcentral.com/1471-2334/10/45)
3. A.A. Albetkova, J.S. Drobeniuc, T.L. Yashina, E.I. Musabayev, **M.O. Favorov**. Genomic Variation Of Hepatitis E Virus From Epidemic And Sporadic Cases. *J. Med. Virology*, 79:1696-1702
4. Complete Sequence Of A Swine Hepatitis E Virus From Kyrgyzstan - L. Lu, J. Drobeniuc, N. Kobylnikov, R. K. Usmanov, B. H. Robertson, M.O. Favorov, Harold S. Margolis; *Journal Of Medical Virology* 74:44, 556-562, Wiley-Liss, Inc., 2004
5. Kalashnikova TV, Bobkova MR, Kovtunen NG, Musabaeva EI, Ongarbaev AB, **Favorov MO**. The evaluation of laboratory workers training in Central Asia for ensuring the quality control principles implementation in the HIV diagnostics. *Klin Lab Diagn.* 2005 Feb; (2):47-51
6. Ongarbaev AB, Avazova DE, Mustafaeva EM, Drobeniuk Zh, Al'betkova AA, Musabaev EI, Kalashnikova TV, **Favorov MO**. Detection of antibodies to HIV virus in saliva by express-tests in Uzbekistan; *Klin Lab Diagn.* 2004 Aug;(8):40-2

7. Netesova IG, Swenson PD, Kalashnikova TV, Netesov SV, **Favorov MO**. HBsAg Subtypes Of Hepatitis B Virus (HBV) In Western Siberian Part Of Russia. *Vir Issues* 2004; 49:17-20
  
8. Kalashnikova TV, Musabaev EI, Usmanov RK, Kuchuk TE, Ongarbaev AB, Mustafaeva EM, Suleimenova Szh, Dzhumagulova A, **Favorov MO**. An Educational Module For Organization Of A System For Controlling Quality Of Laboratory Diagnosis Of Infections For The Central Asia Regions. *Klin Lab Diagn.* 2002 Aug;(8):50-3. PMID: 12362645
  
9. Drobeniuc J, **Favorov MO**, Shapiro CN, Bell BP, Mast EE, Dadu A, Culver D, Iarvoi P, Robertson B, Margolis HS. Hepatitis E Virus Antibody Prevalence Among Persons Who Work In Close Contact With Pigs. *J Infect Dis* 2001;184:1594-1597
  
10. Dzhumagulova AB, Kalashnikova TV, Drobeniuc Zh, Usmanov RK, Dzhumagulova SK, Kuchuk TE, Sharapov MB, Perdi M, **Favorov MO**. The quality of laboratory diagnosis of viral hepatitis and analysis of factors affecting the reliability of results. *Klin Lab Diagn.* 2001 Dec;(12):41-4
  
11. **Favorov MO**, Kosoy MY, Tsarev SA, Childs JE, Margolis HS. Prevalence Of Antibody To Hepatitis E Virus Among Rodents In The United States. *J Infect Dis.* 2000 Feb;181(2):449-55. PMID: 10669325
  
12. **Favorov MO** And Margolis HS. Hepatitis E Virus Infection: An Enterically Transmitted Cause Of Hepatitis. *In: Emerging Infectious Diseases* (3), (W. Michael Scheld Et Al.,Ed), Washington, DC, ASM Press, 1999. Pp. 1-16
  
13. Hutin YJ, Harpaz R, Drobeniuc J, Melnic A, Ray C, **Favorov M**, Iarvoi P, Shapiro CN, Woodruff BA., Injections given in healthcare settings as a major source of acute hepatitis B in Moldova. *Int J Epidemiol.* 1999 Aug;28(4):782-6.
  
14. Webber LM, Grabow WOK, **Favorov MO**, Fields HA. Comparison Of Two Enzyme Immunoassays For The Detection Of Hepatitis E Virus Antibodies. *South Afr J Epidemiol And Infect* 1998;13:16-19
  
15. **Favorov MO**, Nemechek V, Yashina TL, Nazarova OK, Lambert SB, Drobenuk J, Znoiko OO, Shkurko TV, Lvov DK, Onischenko GG, Fields HA, Margolis HS. Current Epidemiological Trends Of Viral Hepatitis In Eastern Europe And The Former Soviet Union. *Viral Hepatitis And Liver Disease* (M. Rezzetto Et Al., Ed), Turin, Italy: Edizioni Minerva Medica, 1997. 555-558
  
16. Mast EE, Kuramota IK, **Favorov MO**, Schenging VR, Burkholder BT, Shapiro CN, Holland PV. Prevalence Of And Risk Factors For Antibody To Hepatitis E Virus Seroreactivity Among Blood Donors In Northern California - *J Infect Dis* 1997;176:34-40

17. Yashina TL, **Favorov MO**, Khudyakov YE, Fields HA, Znoiko OO, Shkurkotv, Bonafonte MT, Sevall JS, Agopian MS, Peter JB. Detection Of Hepatitis G Virus (HGV) RNA, And Clinical Characteristics Of Acute HGV Infection. *J Infect Dis* 1997;175:1302-1307
  
18. Mast EE, **Favorov MO**, Shapiro SN Et Al In: Buisson Y Coursaget P, Kane M, Eds. Hepatitis E Virus Infection In The Americas. Hepatitis E Virus Infection In The Americas - Enterically Transmitted Hepatitis Viruses. Tours, France: La Simarre, 1996. 282-93
  
19. Blitz-Dorfman L, Monsalve F, Atencio R, Porto L, Monzon M, **Favorov MO**, Fields HA, Pujol FH, Echevarria JM . Serological Survey Of Markers Of Infection With Viral Hepatitis Among The Yukpa Amerindians From Western Venezuela. *Annals Of Tropical Medicine & Parasitology* 1996;90:655-7
  
20. **Favorov MO**, Khudyakovye, Mast EE, Yashina TL, Shapiro CN, Khudyakova NS, Jue DL, Onischenko GG, Margolis HS, Fields HA . Igm And Igg Antibody To Hepatitis E Virus (HEV) Detected By An Enzyme Immunoassay Based On HEV-Specific Artificial Recombinant Mosaic Protein. *J Med Virol* 1996;50:50-58
  
21. Karetzi Y, **Favorov MO**, Khudyakova NS, Bar-Shini S, Dagan R, Fields H, Mendelson E. Populations With High Prevalence Of Antibody Against Hepatitis E Virus In Israel. *Clinical And Diagnostic Virology* 1996;6:73-76
  
22. Fields HA, Khudyakov YE, **Favorov MO**, Khudyakova NS, Mian-Er Cong, Hollow BF, Lambert SB. Artificial Mosaic Proteins As New Immunodiagnostic Reagents: The Hepatitis E Virus Experience. *Jue DL Clinical And Diagnostic Virology* 1996;5:167-179
  
23. Arankalle VA, Jha J, **Favorov MO**, Chaudhari A, Fields HA, Banerjee K. Contribution Of HEV And HCV In Causing Fulminant Non-A, Non-B Hepatitis In Western India. *J Viral Hepatitis* 1995;2:189-93
  
24. Pillot J, **Favorov MO**, Grangeot-Keros L, Lazizi Y, Fridman R . Prevalence Des Anticorps Anti-Virus De L'hepatite E Chez La Femme Enciente, En Region Parisienne: Considerations Serologiques [Prevalence Of Hepatitis E Virus Antibodies In Pregnant Women In The Paris Region: Serological Considerations]. *Presse Med* 1995 1995;24:1271
  
25. Semiletov YA, Dementeva EV, Yashina TL, **Favorov MO**, Shibnev VA. Synthesis And Antigenic Activity Of Peptides From The ORF3 Protein Sequence Of Hepatitis E Virus. *J Bioorganic Chem* 1995;21:156-157
  
26. Grabow WO, **Favorov MO**, Khudyakova NS, Taylor MB, Fields HA. Hepatitis E Seroprevalence In Selected Individuals In South Africa. *J Med Virol* 1994 Dec;44(4):384-8. PMID: 7897368

27. Pujol FH, Rodriguez I, Martinez N, Borberg C, **Favorov MO**, Fields HA, Liprandi F. Viral Hepatitis Serological Markers Among Pregnant Women In Caracas, Venezuela: Implication For Perinatal Transmission Of Hepatitis B And C. *GEN* 1994;48:25-8
  
28. Khudyakov YE, **Favorov MO**, Khudyakova NS, Cong M, Padhya N, Jue D., Holloway B, Lambert S, Fields H. Artificial Mosaic Protein Containing Antigenic Epitopes Of The Hepatitis E Virus. *J Virol* 1994; 68:7067-7074
  
29. Robertson BH, Khanna B, **Favorov MO**, Yashina TL, Tratskaya T . A Distinct Genetic Group Of Hepatitis C Virus Circulating Within The Former Soviet Union. *Viral Hepatitis And Liver Disease* (K. Nishioka Et Al., Ed.). Tokyo: Springer-Verlag, 1994. 306-309
  
30. Evidence For Parenterally Transmitted Non-A, Non-B Non-C, Non-D, Non-E Hepatitis In Russia - **Favorov MO**, Znoiko OO, Yashina TL, Patel P, Goldberg EZ, Khudyakov YE, Khanna B, Fields HA, Gorbarets E, Kashrin V, Margolis HS In: *Viral Hepatitis And Liver Disease* (K.Nishioka Et Al., Ed.). Tokyo: Springer-Verlag, 1994. Pp. 87-89
  
31. Prevalence Of Antibodies Against Hepatitis E Virus Among Urban And Rural Populations In Venezuela - Pujol FH, **Favorov MO**, Marcano T, Este JA, Magris HS, Liprandi F, Khudyakov YE, Khudyakova NS, Fields HA *J Med Virol* 1994;42:234-236
  
32. Enzyme Immunoassay For The Detection Of Anti-HEV Activity Based On Synthetic Peptide - **Favorov MO**, Khudyakov YE, Fields HA, Khudyakova NS, Padhay N, Alter MJ, Mast E, Polish L, Yashina TL, Yarasheva DM, Onischenko GG, And Margolis HA, *J Virol Methods* 1994;46:237-250
  
33. V Pujol FH, Rodriguez I, Martinez N, Borberg C, **Favorov MO**, Fields HA, Liprandi F. iral Hepatitis Serological Markers Among Pregnant Women In Caracas, Venezuela: Implication For Perinatal Transmission Of Hepatitis B And C. *G E N*. 1994 Jan-Mar;48(1):25-8. PMID: 7926616
  
34. Khudyakov YuE, **Favorov MO**, Jue DL, Hine TK, Fields HA. Immunodominant antigenic regions in a structural protein of the hepatitis E virus. *Virology* 1994 Jan;198(1):390-3
  
35. Iashina TL, **Favorov MO**, Shakhgil'dian IV, Iarasheva DM, Nazarova OI, Derevianko EN, Ommadova MI, Onishchenko GG, Watanabe Y, Nishioka K Zh. Prevalence Of Hepatitis C In Population Of Central Asia Region. *Mikrobiol Epidemiol Immunobiol* 1993 Sep-Oct;(5):46-9 PMID: 8067143
  
36. Etiology Of Acute Sporadic Non-A, Non-B Hepatitis In India - Arankalle VA, Chobe LP, Jha J, Chadha MS, Banerjee K, **Favorov MO**, Kalinina T, Fields H. E. *J. Med Virol* 1993;40(2): 121-125
  
37. Semiletov IA, Kruglov IV, Karpovava, Iashina TL, **Favorov MO**. A Comparative Study Of The Diagnostic Value Of Peptides, Corresponding To Various Genomic Sequences Of The Hepatitis Delta Virus. *Mol Gen Mikrobiol Virusol* 1993;4:34-7

38. Tretskaya TA, Shakhgildyan IV, Yashina TL, Kravchenko VK, Lyubchak VA, Mikhno LA, Grechishkin VS, Diyachenko AI, And **Favorov MO**. Age Prevalence Of Hepatitis C Antibodies Among A Healthy Population Of The North-West Of Ukraine. *Virology Issues* 1993;38:137-8
  
39. Fields HA, **Favorov MO**, Margolis HA. Prevalence Of Hepatitis C In Population Of Central Asia Region. *J Clin Immunoassay* 1993;16(3):215-223
  
40. Khudyakov YE, Fields HA, **Favorov MO**, Khudyakova NS, Bonafonte MT, Holloway B. Synthetic Gene For The Hepatitis C Virus Nucleocapsid Protein. *Nucleic Acids Research*, 1993;21(11):2747-2754
  
41. **Favorov MO**, Khudyakov YE, Fields HA. Enzyme Immunoassay For The Detection Of Anti-HEV Activity Based On Synthetic Peptide: Seroprevalence And World Distribution Of Hepatitis E Virus-Infection. *Concepts In Virology*, Mahy BWJ And Lvov DK, Eds. Harwood Academic Publishers, London, England, 1993. 183-190
  
42. Khudyakov YE, Khudyakova NS, Fields HA, Jue D, Starling C, **Favorov MO**, Krawczinski K, Polish L, Mast E, Margolis HS. Epitope Mapping In Proteins Of Hepatitis E Virus. *Virology* 1993;194:89-96
  
43. Khudyakov YE., **Favorov MO**, Fields HA. A Small Open Reading Frame Of The Hepatitis Delta Virus Antigenomic RNA Encodes A Protein That Elicits Antibodies In Some Infected Patients. *Virus Research* 1993;27:13-24
  
44. Iushchuk ND, Shestakova IV, Klimova EA, Sergeeva NA, Malyshev NA, Braginskii DM, **Favorov MO**. Clinical Course And Outcome Of Acute Hepatitis B In Relation To Hbeag – Anti-Hbe. *Rossiiskii Meditsinskii Zhurnal* 1992;4:42-4
  
45. **Favorov MO**, Fields HA, Purdy MA, Yashina TL, Aleksandrov AG, Alter M, Yarasheva DM, Margolis HS. Specific Diagnosis Of Viral Hepatitis E Infections By Western Blot Analysis. *J Med Virol* 1992;36:246-50
  
46. **Favorov MO**, Fields HA, Yashina TL, Goldberg EZ, Yeramishntsev AK, Rakchimova HK, Burkov AN, Margolis HS, Lvov DK. Hepatitis C Virus In Chronic Hepatitis And Liver Cirrhosis: Possibility Of Mixed Infections With Parenteral Hepatitis. *J Med Virol* 1992;36:184-87
  
47. Yashina TL, **Favorov MO**, Shakhgildyan IV, Firsova SN, Eraliev AE, Zhukova LD, Reznichenko RG. Occurrence Of Markers Of Virus Hepatitis B And Delta Infections Among Healthy Populations In Regions Of Differing Morbidity. *Virology Issues* 1992;37:194-196

48. Iushchuk ND, Shestakova IV, Klimova EA, Sergeeva NA, Malyshev NA, Braginskiĭ DM, **Favorov MO**. Clinical course and outcome of acute hepatitis B in relation to the markers of the E system. *Ross Med Zh.* 1992;(4):42-4
  
49. Bader TF, Permanente K, Krawczynski K, Polish LB, **Favorov MO**. Hepatitis E In A U.S. Traveler To Mexico. *N Engl J Med* 1991;325:1659
  
50. Yarasheva DM, **Favorov MO**, Yashina TL, Shakhgildian IV, Umarova AA, Sorokina SA, Kamardinov Khk, Mavashev VI. The Etiology Of Acute Viral Hepatitis In Tadjikistan In A Period Of Low Morbidity. *Vopr. Virusol* 1991;36:454-6
  
51. **Favorov MO**, Yashina TL, Znoiko OO, Kashirin VI, Goldberg EZ, Roggendorf M. Antibodies To Virus Hepatitis C (C-100-3) Igm And Igg. *Vopr. Virusol* 1991;4:234-237
  
52. **Favorov MO**, Shakhgil'dian IV, Iashina TL, Onishchenko GG, Firsova SN, Eraliev AE, The Characteristics Of An Outbreak Of Non-A, Non-B Hepatitis With A Fecal-Oral Mechanism Of The Transmission Of The Causative Agent In Osh Province, Kirghiz SSR. *Zh Mikrobiol Epidemiol Immunobiol* 1990;11:37-44
  
53. Nguyen VM, **Favorov MO**, Iashina TL. The Etiology Of Viral Hepatitis Vietnam. *Virology Issues* 1990;35:418-9
  
54. Shakhgildian IV, Chadkha MS, **Favorov MO**, Arankalle VA, Khukhlovich PA, Sehgal A, Iashina TL, Ramamurti SL, Zairov GK. Comparative Study Of Non-A, Non-B Hepatitis With A Fecal-Oral Mechanism Of The Transmission Of The Causative Agent In The USSR And India. *Virology Issues* 1990;35:342-4
  
55. Gurov AV, **Favorov MO**, Iashina TL, Goldberg EZ, Khizhniakova TM, Ananov VA. The Production Of Anti-Hbc Igm Antibodies In Human Lymphocytes Transformed By The Epstein-Barr Virus. *Virology Issues* 1990;35:306-Evstingneeva RP, Zheltukhina GA, Prokuronova EI, Smirnov VD, Semiletov IA, Kalinina TI, Khudiakov IE, Khromov IS, Yashina TL, **Favorov MO** Bioorg Khim. Synthesis And Immunologic Properties Of The Peptide Fragment Of The Hepatitis B Virus Envelope Pres-Protein. 1990;16:34-40
  
56. **Favorov MO**, Gol'dberg EZ, Gurov AV, Zairov GK, Yashina TL. Various Physico-Chemical Properties Of Non-A, Non-B Hepatitis Virus With A Fecal-Oral Route Of Transmission And Specific Diagnosis Of The Illness. *Virology Issues* 1989;34:41-50
  
57. Zairov GK, Stakhanova VM, Listovskaia EK, Konstantinova LA, **Favorov MO**. Electron Microscopic Research In Non-A, Non-B Viral Hepatitis With A Fecal-Oral Mechanism Of Transmission. *Virology Issues* 1986;31:172-5

58. Kuznetsov SV, **Favorov MO**, Mikhailov MI, Ketiladz ES, Bykovskii AF. Morphological Changes In Hepatocytes In Viral Non-A, Non-B Hepatitis. *Virology Issues* 1985;30:615-7
59. Naumova AK, **Favorov MO**, Ketiladze ES, Nosikov VV, Kisselev LL Gene. Nucleotide Sequences In Human Chromosomal DNA From Nonhepatic Tissues Homologous To The Hepatitis B Virus Genome. 1985;35:19-25
60. Bugaeva NP, Mikhailov MI, **Favorov MO**, Ketiladze ES. Value Of Igm And Igg Class Anti-Hbs In The Differential Diagnosis Of Viral Hepatitis B And "Non-A, Non-B". *Virology Issues* 1981;5:621-4;
61. Bugaeva NP, Mikhailov MI, **Favorov MO**, Ketiladze ES. Improvements In The Laboratory Diagnosis Of Hemorrhagic Fever With A Renal Syndrome. *Virology Issues* 1981 Sep-Oct;(5):618-21 PMID: 6121424
62. Ketiladze ES, Vorozhbieva TE, Zhilina NN, Bugaeva NP, **Favorov MO**. Modern Methods Of Diagnosis Of Serum Hepatitis Type B. *Sov Med* 1979;5:40-4

<b>Language Skills:</b>	<b>Language</b>	<b>Spoken</b>	<b>Written</b>	<b>Reading</b>
	English	Advanced	Advanced	Advanced
	Russian (native)	Advanced	Advanced	Advanced
	Turkmen	Intermediate	Novice	Novice
	Ukrainian	Intermediate	Novice	Novice